Oryzon Genomics - Maturing ALICE trial dataset continues to impress

On 9 December 2019, Oryzon presented more data from the Phase II ALICE trial at the 61st ASH annual meeting in Orlando, Florida. The single-arm, open-label study enrolled newly diagnosed, elderly acute myeloid leukaemia (AML) patients and investigated iadademstat in combination with standard of care chemotherapy drug azacitidine. Six of the eight evaluable patients (75%) achieved objective (OR) responses, which was in line with the first results reported in June 2019. For comparison, OR rates are 25–32% in AML patients treated with azacitidine monotherapy. Our valuation is €437m or €9.5/share.